Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Sarepta’s new CEO Michael Severino faces critical milestones to prove growth
In his first earnings call just days after becoming Sarepta Therapeutics | In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare disease drugmaker faces multiple upcoming milestones to clarify its growth trajectory.
TL;DRAI
Sarepta CEO Michael Severino inherits critical FDA decisions by Feb 2027 on gene therapy Elevidys (Q2: $98M, -4% QoQ) amid new competition in exon-skipping treatments. Regulatory delays signal consolidation in gene therapy; impacts biotech M&A valuations and VC portfolio timing.
848 words~4 min read
